Navigation Links
Malaria product portfolio would benefit from greater cohesion amongst stakeholders

Malaria drug and vaccine research is booming. According to a report launched today in the UK by Australian researchers at The George Institute for International Health, 16 new malaria vaccine candidates are now in clinical trials; six new malaria drugs are about to reach the market; and by 2011 we will have up to 12 new anti-malarial drug product registered.

However, this unprecedented level of malaria R&D activity is not necessarily all good news. The reports authors found that the high number of malaria vaccine candidates was the result of scientific and technical gaps and lacking policy coordination rather than a reflection of cohesive global activity. Lack of coordination and planning mean that invested funding and efforts are not delivering as much as they should, and may be costing donors tens of millions of dollars.

According to Dr Mary Moran, the reports lead author, improved vaccine research co-ordination and investment decisions could save more than USD20 million over 5 years and prevent up to 3,000 unnecessary test vaccinations in African children. The most tantalizing finding was that these high-impact policy interventions and the resulting savings - are well within reach if donors and developers can work together, said Dr Moran. We need a system to ensure that fewer and better vaccine candidates enter clinical trials in Africa.

On the drug front, the report welcomed the arrival of new anti-malarials after a dearth of many decades, but noted that this meant donors, purchasers and developing countries are now faced with the challenge of working out which of the many competing products offer the best cost-benefit for African populations, and the funding of very large and expensive studies which are needed to determine this. Post-registration trials of tens to hundreds of thousands of patients will be needed to ensure that these new drugs are appropriately absorbed by already strained health systems and appropriately delivered to malaria patients.

Over the past year, Dr Mary Moran and her team from The George Institute, supported by the Global Forum for Health Research through World Bank funding, engaged with main stakeholders in the malaria field to provide donors with a 5-year map of the future, including what malaria products are in the pipeline, how much donors will need to spend to move them towards success, and where this spending should focus. Key findings were:

  • The additional cost for clinical development of the global malaria vaccine and drug portfolio over the next 5 years is likely to be around $US 600 million
  • A substantial proportion of this (e.g. up to 60% in the case of vaccine trials) will go to Africa. This represents a very large injection of business funding into Africa
  • Up to US $250 million may go to small Western drug companies and Contract Research Organizations and to developing country manufacturers: again, a substantial injection of funds into desired growth areas.

The report also debunks some common beliefs about African capacity (or lack thereof). In particular, the notion that Africa needs investment to build new malaria trial sites, and that existing African trial sites could be sustainable if they were only more business-like. Sustainability is a myth, said Dr Moran, at least under current conditions. Currently, many donors and developers strangle a sites ability to stay afloat because they routinely pay project overheads that are well below costs, and are resistant to providing core funding. No Western institution could survive under those conditions.

More encouragingly, the report noted that well-planned and sustained donor investment since 2000 means that, if well managed, we now have enough malaria trial sites in Africa to meet all likely future demand out to 2012 and probably well beyond. Funders and trial sites can justly congratulate themselves on their site capacity-building efforts in Africa in the last 10 years, said Dr Moran. However, this also means the time has come to move on from building new product trial sites in Africa to supporting current sites in a sustainable way.

The key to success in the next five years will be providing the right amount of funding in the right places supported by the right policies, said Professor Stephen Matlin, Executive Director of the Global Forum for Health Research. We hope this report helps donors and product developers reach that goal.

WHO estimates that 300 - 500 million new malaria infections occur per year, resulting in more than 1.2 million deaths annually. The overwhelming majority of these deaths are in children under five years of age and in pregnant women.


Contact: Chris Fowler
Research Australia

Related medicine news :

1. Feeding channel created by malaria parasite - a new target for malaria treatments
2. Hundred million dollar gift for malaria institute
3. Malaria strikes Munger tribals
4. Sponging Cattle betters spraying in eradicating Malaria
5. Misleading anti-malarial drug
6. Garlic fights malaria and cancer
7. Gene researchers make Malaria-resistant mosquito
8. More Treatment Options For Malaria
9. Scientists Unveil Mechanism Behind Resistance to Severe Malaria
10. New initiative launched to fight malaria by repelling mosquitoes
11. Jharkhand reports 13,000 Malaria cases
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... The ... perfect dish and pleasing the palates of attendees is of the utmost importance. ... to a seasonal get-together, give these recipes a try this holiday season. , ...
(Date:11/25/2015)... Nairobi (PRWEB) , ... November 26, 2015 , ... ... African Union Commission (AUC), European Union (EU), ANDI Pan African Centres of Excellence, ... Nations Office in Nairobi (UNON) for the opening of the 5th African Network ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dental professionals who would like ... , are invited to attend Dr. Mark Iacobelli’s Advanced Implant Mentoring (AIM) CE course. ... OH. , As the co-founders of Advanced Implant Mentoring (AIM), Dr. Iacobelli and ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... Smiles ... of TMJ Disorder, Bruxism, and moderate facial wrinkling. While many patients are aware of ... of the great success Botox® delivers to those suffering with discomfort, soreness, and pain ...
(Date:11/25/2015)... ... , ... “While riding the bus, I saw a passenger in a wheelchair ... to be a convenient and comfortable way to protect them from bad weather, so ... safely travel during cold or inclement weather. In doing so, it ensures that the ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , Nov. 25, 2015  Linden Care, LLC, a ... treatment outcomes for patients suffering from chronic pain, said ... a Temporary Restraining Order (TRO) enjoining Express Scripts from ... companies. --> --> ... of its legal options. --> ...
(Date:11/25/2015)... AVIV, Israel , November 25, 2015 ... (NASDAQ: KTOV ) (TASE: KTOV), a biopharmaceutical company ... simultaneous treatment of various clinical conditions, today announced the ... 3,158,900 American Depository Shares ( ADSs ), each representing ... purchase up to 3,158,900 ADSs. The ADSs and warrants ...
(Date:11/25/2015)... , Nov. 25, 2015 Endo International plc (NASDAQ: ... De Silva , President and CEO, will discuss corporate updates ... in New York on Wednesday, December ... . Click on Investor Relations, and then the link to ... the presentation,s start time to visit the site and download ...
Breaking Medicine Technology: